The pharmacokinetics and pharmacogenomics of voriconazole in pediatric Saudi patients: advancing toward precision medicine.
7 affiliations
- 1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
- 2Pharmaceutical Sciences Department, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia.
- 3King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
- 4The Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia.
- 5Pediatric Infectious Diseases and Antimicrobial Stewardship, Pediatric Subspeciality Department, Children's Specialized Hospital, King Fahad Medical City, Riyadh, Saudi Arabia.
- 6Clinical Pharmacy Department, Pharmacy Administration, King Fahad Medical City, Riyadh, Saudi Arabia.
- 7Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Abstract
Background
Voriconazole is a broad-spectrum triazole antifungal. It is used to prevent and treat invasive fungal infections in immunocompromised pediatric patients. Its clinical use is limited due to its nonlinear pharmacokinetics, high variability, and a narrow therapeutic index. Data on pharmacogenomic effects in pediatric patients are limited, particularly in the Saudi population. This study aimed to evaluate voriconazole pharmacokinetics in pediatric patients and to assess the impact of CYP2C19 genotypes on drug concentrations and clearance.Methods
A prospective observational study was conducted from October 2022 to October 2024 at two tertiary care centers in Riyadh, Saudi Arabia. Saudi pediatric patients aged between 1 and 14 years receiving voriconazole were enrolled after informed consent from guardians. Trough blood samples were collected on the fifth day of therapy and CYP2C19 genotyping (*2, *3, *17) was performed. The metabolizer status was assigned according to the Clinical Pharmacogenetics Implementation Consortium guidelines.Results
Forty patients were included. The mean age was 67.7 ± 44.1 months, and the mean weight was 17.8 ± 9.5 kg CYP2C19 phenotypes were distributed as follows: normal metabolizers (65%), rapid metabolizers (17.5%), intermediate metabolizers (10%), and ultrarapid metabolizers (7.5%). No poor metabolizers were observed. The mean voriconazole trough concentration was 2.26 ± 2.68 mg/L and the majority (52.5%) of patients had subtherapeutic levels, 35% were within range, and 12.5% were supratherapeutic. In the multivariable analysis, only weight was significantly associated with clearance (R ² = 0.14, P-value = 0.02), whereas genotype showed no significant effect (P-value = 0.48).Conclusion
Voriconazole trough concentrations showed considerable variability among pediatric patients. Thirty-five percent of patients achieved therapeutic trough concentrations at the first trough assessment and no statistically significant association between CYP2C19 polymorphisms and voriconazole trough concentrations was observed in this cohort. However, the small sample size may have limited the detection of genetic influences. These findings support the conclusion that individualized dosing is needed to optimize therapy.
Related
- Physiologically Based Pharmacokinetic Modeling of Venetoclax in Pediatric Acute Myeloid Leukemia: Food Effects, Age-Related Pharmacokinetics, and Voriconazole-Mediated Drug-Drug Interactions.
- Population pharmacokinetics and model-informed precision dosing of busulfan in Chinese pediatric allogeneic hematopoietic stem cell transplantation: a prospective real-world cohort study
- Evaluation of Voriconazole Population Pharmacokinetics in Japanese Patients and Factors Influencing Prediction Accuracy: A Machine Learning Approach
- Implementation of Pharmacogenomics in Pediatric-Focused Institutions Within the Pharmacogenomics Global Research Network.
- Editorial: Artificial intelligence and anti-cancer drugs: advancing discovery, personalization, and precision oncology
BibTeX
@article{albassam2026pharmacokinetics,
title = {{The pharmacokinetics and pharmacogenomics of voriconazole in pediatric Saudi patients: advancing toward precision medicine.}},
author = {Ahmed Albassam and Abeer Alharbi and Hala Al Anizi and Badr Almuzzaini and Waleed Alhussaini and Alaa Aldahri and Amani Kurdi and Laila Alawdah and Sameh Awwad and Sara Almuhisen and Abdullah Alsultan and Majed Aljeraisy},
journal = {Frontiers in pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1959131},
url = {https://europepmc.org/article/MED/42908656},
note = {CC BY},
}
RIS
TY - JOUR
TI - The pharmacokinetics and pharmacogenomics of voriconazole in pediatric Saudi patients: advancing toward precision medicine.
AU - Ahmed Albassam
AU - Abeer Alharbi
AU - Hala Al Anizi
AU - Badr Almuzzaini
AU - Waleed Alhussaini
AU - Alaa Aldahri
AU - Amani Kurdi
AU - Laila Alawdah
AU - Sameh Awwad
AU - Sara Almuhisen
AU - Abdullah Alsultan
AU - Majed Aljeraisy
PY - 2026
DA - 2026/10/07
JO - Frontiers in pharmacology
DO - 10.3389/fphar.2026.1959131
UR - https://europepmc.org/article/MED/42908656
AB - Background Voriconazole is a broad-spectrum triazole antifungal. It is used to prevent and treat invasive fungal infections in immunocompromised pediatric patients. Its clinical use is limited due to its nonlinear pharmacokinetics, high variability, and a narrow therapeutic index. Data on pharmacogenomic effects in pediatric patients are limited, particularly in the Saudi population. This study aimed to evaluate voriconazole pharmacokinetics in pediatric patients and to assess the impact of CYP2C19 genotypes on drug concentrations and clearance.Methods A prospective observational study was conducted from October 2022 to October 2024 at two tertiary care centers in Riyadh, Saudi Arabia. Saudi pediatric patients aged between 1 and 14 years receiving voriconazole were enrolled after informed consent from guardians. Trough blood samples were collected on the fifth day of therapy and CYP2C19 genotyping (*2, *3, *17) was performed. The metabolizer status was assigned according to the Clinical Pharmacogenetics Implementation Consortium guidelines.Results Forty patients were included. The mean age was 67.7 ± 44.1 months, and the mean weight was 17.8 ± 9.5 kg CYP2C19 phenotypes were distributed as follows: normal metabolizers (65%), rapid metabolizers (17.5%), intermediate metabolizers (10%), and ultrarapid metabolizers (7.5%). No poor metabolizers were observed. The mean voriconazole trough concentration was 2.26 ± 2.68 mg/L and the majority (52.5%) of patients had subtherapeutic levels, 35% were within range, and 12.5% were supratherapeutic. In the multivariable analysis, only weight was significantly associated with clearance (R ² = 0.14, P-value = 0.02), whereas genotype showed no significant effect (P-value = 0.48).Conclusion Voriconazole trough concentrations showed considerable variability among pediatric patients. Thirty-five percent of patients achieved therapeutic trough concentrations at the first trough assessment and no statistically significant association between CYP2C19 polymorphisms and voriconazole trough concentrations was observed in this cohort. However, the small sample size may have limited the detection of genetic influences. These findings support the conclusion that individualized dosing is needed to optimize therapy.
SN - 1663-9812
ER -